2012
DOI: 10.4172/2161-0509.1000109
|View full text |Cite
|
Sign up to set email alerts
|

Immune Enteral Nutrition Can Improve Outcomes in Medical-Surgical Patients with ARDS: A Prospective Randomized Controlled Trial

Abstract: Objective To determine if early continuous enteral feeding of a diet containing eicosapentaenoic acid (EPA), gamma-linolenic acid (GLA), docosahexaenoic acid, and antioxidants in surgical-medical patients with ARDS improves Lung Injury Score (LIS), gas exchange, Multiple Organ Dysfunction (MOD) Score, ICU length of stay, and days on mechanical ventilation. Methods Prospective randomized 2-center double-blind controlled trial of 17 ARDS patients whom continuously tube-fed the experimental diet (n=9) or an iso… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
53
0
5

Year Published

2013
2013
2021
2021

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 31 publications
(60 citation statements)
references
References 41 publications
2
53
0
5
Order By: Relevance
“…There were a total of 4 new RCTs of enteral fish oils, borage oils, and antioxidants published since the 2009 CCPGs, 11 , 30 32 and with the addition of the data from these, the effect on mortality decreased from relative risk (RR) = 0.67, 95% confidence interval (CI) = 0.51, 0.87, P = .003, heterogeneity I 2 = 0% to RR = 0.84, 95% CI = 0.56, 1.26, P = .39, heterogeneity I 2 = 61% (see Figure 1). There were concerns about the adequacy of the control group in 1 large multicenter study 11 in which patients received significantly more protein.…”
Section: Update Of the Ccpgsmentioning
confidence: 99%
“…There were a total of 4 new RCTs of enteral fish oils, borage oils, and antioxidants published since the 2009 CCPGs, 11 , 30 32 and with the addition of the data from these, the effect on mortality decreased from relative risk (RR) = 0.67, 95% confidence interval (CI) = 0.51, 0.87, P = .003, heterogeneity I 2 = 0% to RR = 0.84, 95% CI = 0.56, 1.26, P = .39, heterogeneity I 2 = 61% (see Figure 1). There were concerns about the adequacy of the control group in 1 large multicenter study 11 in which patients received significantly more protein.…”
Section: Update Of the Ccpgsmentioning
confidence: 99%
“…Ìè âèä³ëèëè â³ñ³ì äîñë³äaeåíü [233][234][235][236][237][238][239][240], ïðèñâÿ÷åíèõ öüîìó ïèòàííþ; â ÷îòèðüîõ ç íèõ òàêîae çàñòîñîâóâàëèñü àíòèîêñèäàíòè. Ìåòà-àíàë³ç íå âèÿâèâ aeîäíèõ ïåðåâàã (äèâ.…”
Section: êîìåíòàð äî ðåêîìåíäàö³é 30-32unclassified
“…1): [38][39][40][41][42][43][44][45] para la síntesis de ATP y 2,3-difosfoglicerato, imprescindibles en la función pulmonar. El riesgo de realimentación es frecuente en estos pacientes que se encuentran en estado carencial por lo que se debe sospechar y tratar (27,28).…”
Section: Soporte Nutricional En El Paciente Epoc (Fig 1)unclassified
“…Pero hasta el momento, los estudios han sido contradictorios en demostrar la eficacia clínica de las dietas con combinaciones de grasas ricas en ácidos eicosapentanoico (EPA), docosahexaenoico (DHA), γ-linolénico (GLA) y antioxidantes en el complejo mundo de la LPA y el SDRA (42)(43)(44)(45)(46)(47)(48)(49)(50)(51). La heterogenicidad de los estudios, la ausencia de información sobre el manejo clíni-co, la utilización de fórmulas con mezclas de farmaconutrientes y la disparidad de resultados hacen que no se pueda recomendar el uso rutinario de estas fórmulas enterales (52).…”
Section: Soporte Nutricional En El Paciente Con Lpa Y Sdra (Fig 1)unclassified
See 1 more Smart Citation